Answers are grounded in this paper and cite their sources.
In an international registry analysis of 201 patients with SM-AHN, KIT D816V-selective TKI exposure was associated with longer overall survival (37.9 vs 17.8 months; P <.001) and lower 36-month incidence of acute myeloid leukemia transformation (5.9% vs 27.1%; P <.001).
No takes yet. Share an insight, caveat, or question.
Hermine et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: